$7.61
0.52% today
Nasdaq, Feb 28, 05:18 pm CET
ISIN
US50127T1097
Symbol
KURA
Sector
Industry

Kura Oncology, Inc. Stock price

$7.65
-0.26 3.29% 1M
-12.63 62.28% 6M
-1.06 12.17% YTD
-14.11 64.84% 1Y
-8.22 51.80% 3Y
-4.47 36.88% 5Y
-7.35 49.00% 10Y
Nasdaq, Closing price Thu, Feb 27 2025
-0.12 1.54%
ISIN
US50127T1097
Symbol
KURA
Sector
Industry

Key metrics

Market capitalization $594.89m
Enterprise Value $156.22m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 1.40
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-217.50m
Free Cash Flow (TTM) Free Cash Flow $-169.24m
Cash position $727.40m
EPS (TTM) EPS $-2.36
P/E forward negative
Short interest 10.49%
Show more

Is Kura Oncology, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,809 stocks worldwide.

Kura Oncology, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

15 Analysts have issued a Kura Oncology, Inc. forecast:

12x Buy
80%
3x Hold
20%

Analyst Opinions

15 Analysts have issued a Kura Oncology, Inc. forecast:

Buy
80%
Hold
20%

Financial data from Kura Oncology, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
- -
-
100%
- Direct Costs 0.86 0.86
2% 2%
-
-0.86 -0.86
2% 2%
-
- Selling and Administrative Expenses 66 66
39% 39%
-
- Research and Development Expense 150 150
43% 43%
-
-217 -217
41% 41%
-
- Depreciation and Amortization 0.86 0.86
2% 2%
-
EBIT (Operating Income) EBIT -218 -218
41% 41%
-
Net Profit -198 -198
38% 38%
-

In millions USD.

Don't miss a Thing! We will send you all news about Kura Oncology, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Kura Oncology, Inc. Stock News

Neutral
Seeking Alpha
one day ago
Kura Oncology, Inc. (NASDAQ:KURA ) Q4 2024 Earnings Conference Call February 26, 2025 4:30 PM ET Company Participants Patti Bank - IR Troy Wilson - President and CEO Mollie Leoni - CMO Tom Doyle - SVP of Finance and Accounting Brian Powl - CCO Conference Call Participants Li Watsek - Cantor Fitzgerald Yen-Der Li - Leerink Partners Jason Zemansky - Bank of America Peter Lawson - Barclays Dara Az...
Neutral
GlobeNewsWire
2 days ago
– KOMET-001 registrational trial in R/R NPM1-mutant AML achieved primary endpoint – – Alignment reached with FDA and EMA on key aspects of the KOMET-017 protocol including use of MRD-negative CR endpoint for potential U.S. accelerated approval pathway in frontline intensive chemotherapy trial – – Topline MRD-negative CR results from KOMET-017-IC Phase 3 trial anticipated in 2028 – – Multiple da...
Neutral
GlobeNewsWire
3 days ago
SAN DIEGO, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to participate in three upcoming investor conferences:
More Kura Oncology, Inc. News

Company Profile

Kura Oncology, Inc. operates as a clinical-stage biopharmaceutical company which engages in the research and development of medicines for the treatment of cancer. Its pipeline includes Tipifarnib which is a Farnesyl transferase inhibitor for HRAS Mutant Solid Tumors, Chronic Myelomonocytic Leukemia; KO-947 which is an ERK inhibitor for MAPK Pathway Tumors; and KO-539 which is a Menin MLL inhibitor for acute leukemias. The company was founded by Troy E. Wilson, Yi Liu, Pingda Ren and Antonio Gualberto on August 22, 2014 and is headquartered in La Jolla, CA.

Head office United States
CEO Troy Wilson
Founded 2014
Website www.kuraoncology.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today